Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | President and CSO | December 28, 2020 | December 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 676,900 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 676,900 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
Korsana Biosciences, Inc.
Report date December 28, 2020 · Filed December 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,648 |
Reported balance
After 2020-12-28 transaction · row 1
1 source rowRow 1 · 2020-12-28 · Sale · Disposed 20,107 · Balance 251,648 F1: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2019 Filed Apr 3, 2019 22:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023438 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,963 F1 · price: In connection with the separation (the "Separation"), of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received 1,483 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The award vests as shares of Class A Common Stock on May 9, 2019. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 514,698 | $0.00 Strike: $14.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 8 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,698 Underlying: Common Stock · 514,698 shares Expires 2029-01-29 F1 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 ("the Separation"). F8 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2019. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 140,984 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 7 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,984 Underlying: Common Stock · 140,984 shares Expires 2028-02-21 F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2018. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 113,413 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 6 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,413 Underlying: Common Stock · 113,413 shares Expires 2027-02-27 F1 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 ("the Separation"). F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2017. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,794 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 5 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,794 Underlying: Common Stock · 50,794 shares Expires 2026-03-01 F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 4 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-03-01 F4 · derivative.exercise_date: This footnote has been amended to reflect the number of unvested options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. This option to purchase 25,208 shares vests in equal installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,500 shares as of the date hereof. F4 · balance_after: This footnote has been amended to reflect the number of unvested options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. This option to purchase 25,208 shares vests in equal installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,500 shares as of the date hereof. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 27,772 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,772 Underlying: Common Stock · 27,772 shares Expires 2023-02-01 F2 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,490 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 2 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,490 Underlying: Common Stock · 17,490 shares Expires 2022-02-01 F2 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 37,279 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 1 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,279 Underlying: Common Stock · 37,279 shares Expires 2021-02-01 F1 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 ("the Separation"). F2 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| March 08, 2019 Filed Mar 8, 2019 22:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 49,500 | $13.15 | $650,925.00 |
DisclosureSEC source: 0001209191-19-018232 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,480 F1 · kind: Mark Currie sold the shares of common stock of Ironwood Pharmaceuticals, Inc. to raise proceeds to fund a portion of his commitment to purchase shares of common stock of Cyclerion Therapeutics, Inc. alongside other investors in a private placement. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 22:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 225,500 | $13.29 | $2,996,895.00 |
DisclosureSEC source: 0001209191-19-018232 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,980 F1 · kind: Mark Currie sold the shares of common stock of Ironwood Pharmaceuticals, Inc. to raise proceeds to fund a portion of his commitment to purchase shares of common stock of Cyclerion Therapeutics, Inc. alongside other investors in a private placement. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.94 to $13.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:49 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 13 | $14.32 | $186.16 |
DisclosureSEC source: 0001209191-19-012637 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,480 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:49 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,631 | $14.31 | $23,339.61 |
DisclosureSEC source: 0001209191-19-012637 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,493 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:32 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option(Right to Buy) · Derivative | 600,000 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006221 · doc4.xml · derivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Class A Common Stock · 600,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001512 · doc4.xml · derivative · entry 4 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2019-07-28 F2 · kind: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 40,000 shares of Class B Common Stock. The option vests in two equal installments upon the Issuer's achievement of certain regulatory and commercial milestones. The option has vested as to 20,000 shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001512 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 20,000 shares Expires 2019-07-28 F2 · kind: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 40,000 shares of Class B Common Stock. The option vests in two equal installments upon the Issuer's achievement of certain regulatory and commercial milestones. The option has vested as to 20,000 shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherClass A Common Stock | 775,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-001512 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805,124 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherClass B Common Stock | 775,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-001512 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,615 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · derivative · entry 16 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,770 Underlying: Class A Common Stock · 41,615 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2016. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 34,480 | $0.00 Strike: $11.11 | $0.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · derivative · entry 15 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,041 Underlying: Class A Common Stock · 34,480 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, granted as an annual performance award, vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2011 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2015. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 40,556 | $0.00 Strike: $11.25 | $0.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · derivative · entry 14 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Class A Common Stock · 40,556 shares Expires 2020-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2010 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2014. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 116,651 | $17.53 | $2,044,892.03 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 9 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,124 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.22 to $17.79, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 41,615 | $10.24 | $426,137.60 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 8 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 34,480 | $11.11 | $383,072.80 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 7 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 40,556 | $11.25 | $456,255.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 6 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,615 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · derivative · entry 13 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,385 Underlying: Class A Common Stock · 41,615 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2016. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 34,479 | $0.00 Strike: $11.11 | $0.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · derivative · entry 12 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,521 Underlying: Class A Common Stock · 34,479 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, granted as an annual performance award, vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2011 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2015. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 40,556 | $0.00 Strike: $11.25 | $0.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · derivative · entry 11 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,444 Underlying: Class A Common Stock · 40,556 shares Expires 2020-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2010 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2014. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 22,194 | $18.75 | $416,137.50 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 5 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,124 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.37 to $19.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 94,456 | $17.94 | $1,694,540.64 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 4 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,318 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.37 to $18.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 41,615 | $10.24 | $426,137.60 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 34,479 | $11.11 | $383,061.69 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 40,556 | $11.25 | $456,255.00 |
DisclosureSEC source: 0001209191-18-054598 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,666 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001209191-18-048664 · doc4.xml · derivative · entry 8 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class B Common Stock · 6,666 shares Expires 2019-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in two equal installments based on the issuer's achievement of certain regulatory and commercial milestones. Upon achievement of a regulatory milestone, the option vested as to 20,000 shares of Class B Common Stock on January 4, 2017. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,667 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-18-048664 · doc4.xml · derivative · entry 7 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 41,667 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-18-048664 · doc4.xml · derivative · entry 6 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 16,667 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was fully vested as of its grant date of February 12, 2009. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 65,000 | $18.39 | $1,195,350.00 |
DisclosureSEC source: 0001209191-18-048664 · doc4.xml · nonDerivative · entry 4 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.21 to $18.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 6,666 | $5.48 | $36,529.68 |
DisclosureSEC source: 0001209191-18-048664 · doc4.xml · nonDerivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 41,667 | $4.89 | $203,751.63 |
DisclosureSEC source: 0001209191-18-048664 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 16,667 | $4.89 | $81,501.63 |
DisclosureSEC source: 0001209191-18-048664 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · derivative · entry 15 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,666 Underlying: Class B Common Stock · 6,667 shares Expires 2019-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in two equal installments based on the issuer's achievement of certain regulatory and commercial milestones. Upon achievement of a regulatory milestone, the option vested as to 20,000 shares of Class B Common Stock on January 4, 2017. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,666 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · derivative · entry 14 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,667 Underlying: Class B Common Stock · 41,666 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · derivative · entry 13 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Class B Common Stock · 16,667 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was fully vested as of its grant date of February 12, 2009. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 65,000 | $18.39 | $1,195,350.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 8 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 6,667 | $5.48 | $36,535.16 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 7 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 41,666 | $4.89 | $203,746.74 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 6 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 16,667 | $4.89 | $81,501.63 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 5 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · derivative · entry 12 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Class B Common Stock · 6,667 shares Expires 2019-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in two equal installments based on the issuer's achievement of certain regulatory and commercial milestones. Upon achievement of a regulatory milestone, the option vested as to 20,000 shares of Class B Common Stock on January 4, 2017. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,667 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · derivative · entry 11 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Class B Common Stock · 41,667 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · derivative · entry 10 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Class B Common Stock · 16,666 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was fully vested as of its grant date of February 12, 2009. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.